SSY Group (HKSE:02005) 3-Year EPS without NRI Growth Rate : 30.00% (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is SSY Group 3-Year EPS without NRI Growth Rate?

SSY Group's EPS without NRI for the six months ended in Dec. 2023 was HK$0.23.

During the past 12 months, SSY Group's average EPS without NRI Growth Rate was 17.60% per year. During the past 3 years, the average EPS without NRI Growth Rate was 30.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 7.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 11.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of SSY Group was 30.00% per year. The lowest was -15.70% per year. And the median was 11.00% per year.

Competitive Comparison of SSY Group's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, SSY Group's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SSY Group's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SSY Group's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where SSY Group's 3-Year EPS without NRI Growth Rate falls into.

SSY Group 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

SSY Group (HKSE:02005) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

SSY Group 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of SSY Group's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

SSY Group (HKSE:02005) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SSY Group Ltd (HKSE:02005) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

Central Plaza, 18 Harbour Road, Rooms 4902-03, 49th Floor, Wanchai, Hong Kong, HKG

Website

http://www.ssygroup.com.hk

SSY Group Ltd is engaged in the research, development, manufacturing and selling of a wide range of pharmaceutical products, which includes finished medicines of mainly intravenous infusion solution and ampoule injection to hospitals and distributors, bulk pharmaceuticals and medical materials. The company has two reportable segments including intravenous infusion solution and others and medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products, followed by medical materials.

SSY Group (HKSE:02005) Headlines

No Headlines